Cytomegalovirus and other herpesviruses after hematopoietic cell and solid organ transplantation: From antiviral drugs to virus-specific T cells
T Ivana, P Robert, S Pavel, T Lenka, K Irena - Transplant Immunology, 2022 - Elsevier
Herpesviruses can either cause primary infection or may get reactivated after both
hematopoietic cell and solid organ transplantations. In general, viral infections increase post …
hematopoietic cell and solid organ transplantations. In general, viral infections increase post …
The direct and indirect consequences of cytomegalovirus infection and potential benefits of vaccination
P Griffiths - Antiviral research, 2020 - Elsevier
Active infection with cytomegalovirus (CMV) occurs in patients who are
immunocompromised and may produce the high viral loads required to cause end-organ …
immunocompromised and may produce the high viral loads required to cause end-organ …
[HTML][HTML] Impact of cytomegalovirus replication in patients with aggressive B cell lymphoma treated with chimeric antigen receptor T cell therapy
E Márquez-Algaba, G Iacoboni, B Pernas… - … and Cellular Therapy, 2022 - Elsevier
Data are scarce on cytomegalovirus (CMV) replication in patients receiving CD19-directed
chimeric antigen receptor (CAR) T cell treatment. Here we describe the incidence, severity …
chimeric antigen receptor (CAR) T cell treatment. Here we describe the incidence, severity …
[HTML][HTML] Cost effectiveness of letermovir for cytomegalovirus prophylaxis compared with pre-emptive therapy in allogeneic hematopoietic stem cell transplant …
A Sepassi, IM Saunders, M Bounthavong… - PharmacoEconomics …, 2023 - Springer
Purpose The aim of this study was to assess the cost effectiveness of letermovir prophylaxis
with the option for subsequent pre-emptive therapy (PET) for the prevention of …
with the option for subsequent pre-emptive therapy (PET) for the prevention of …
Updates on antiviral drugs for cytomegalovirus prevention and treatment
CN Kotton - Current Opinion in Organ Transplantation, 2019 - journals.lww.com
Updates on antiviral drugs for cytomegalovirus prevention an... : Current Opinion in Organ
Transplantation Updates on antiviral drugs for cytomegalovirus prevention and treatment …
Transplantation Updates on antiviral drugs for cytomegalovirus prevention and treatment …
Evaluation of an electronic, patient‐focused management system aimed at preventing cytomegalovirus disease following solid organ transplantation
C Ekenberg, C da Cunha‐Bang… - Transplant Infectious …, 2020 - Wiley Online Library
Background Cytomegalovirus (CMV) infection is common among solid organ transplant
(SOT) recipients and may cause CMV disease. To optimize the implementation of existing …
(SOT) recipients and may cause CMV disease. To optimize the implementation of existing …
[HTML][HTML] Cytomegalovirus viremia as a risk factor for mortality in HIV-associated cryptococcal and tuberculous meningitis
CP Skipper, KH Hullsiek, FV Cresswell… - International Journal of …, 2022 - Elsevier
Objectives CMV viremia is associated with increased mortality in persons with HIV. We
previously demonstrated that CMV viremia was a risk factor for 10-week mortality in …
previously demonstrated that CMV viremia was a risk factor for 10-week mortality in …
[HTML][HTML] Performance evaluation of the Aptima CMV quant assay using plasma and non-plasma samples
A Lima, V Healer, L Rowe, S Silbert - Journal of Clinical Virology, 2023 - Elsevier
Background Cytomegalovirus (CMV) infection has a major negative impact on
transplantation and is associated with increased morbidity and mortality in this patient …
transplantation and is associated with increased morbidity and mortality in this patient …
New vaccines and antiviral drugs for cytomegalovirus
P Griffiths - Journal of Clinical Virology, 2019 - Elsevier
The natural history of cytomegalovirus (CMV) infection in transplant patients has been well
established. This virus may originate from the recipient, the donor or both. When pre …
established. This virus may originate from the recipient, the donor or both. When pre …
Prospective assessment of cytomegalovirus immunity in high-risk donor-seropositive/recipient-seronegative liver transplant recipients receiving either preemptive …
AP Limaye, ML Green, BC Edmison… - The Journal of …, 2019 - academic.oup.com
The differential impact of preemptive therapy (PET) and antiviral prophylaxis (AP) on
development of cytomegalovirus (CMV)–specific neutralizing antibody (nAb) and T-cell …
development of cytomegalovirus (CMV)–specific neutralizing antibody (nAb) and T-cell …